Drugs / TBio-6517
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04301011 | Jun 2020 → Jan 2023 | cervical cancer, colorectal cancer, cutaneous melanoma, mesothelioma +3 | Turnstone Biologics, Corp. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBio-6517 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04301011 ↗ |
| Route | Intravenous | “TBio-6517 administered by direct injection into tumor(s) or by intravenous infusion” NCT04301011 ↗ |
| Route | Other | “TBio-6517 administered by direct injection into tumor(s) or by intravenous infusion” NCT04301011 ↗ |